97. Comparison of commercially available ELISA kits for accurate detection of antibodies against African swine fever virus Virginia Friedrichs1 , Tessa Carrau1 , Martin Beer1 , Sandra Blome1 1) Friedrich-Loeffler-Institut, Institute for diagnostic virology, Suedufer 10, 17493 Greifswald, Germany Corresponding author: Virginia.Friedrichs@fli.de
Rapid spread of African swine fever virus (ASFV), an enveloped, double-stranded DNA virus causing severe disease with often high fatality rates in Eurasian suids, remains a threat for local pig populations and economies. In Germany, seroprevalence rates are continuously increasing after 1.5 years of virus circulation in the affected Federal States of Brandenburg and Saxony. Moreover, some recently emerged ASFV variants might result in a lower lethality in infected individuals and thus a higher number of recovered, sero-positive and virus negative pigs. To accurately track the evolution of seroprevalence and aid the understanding of disease dynamics reliable serological data and accurate assessment of antibody titers is key. However, samples with antibody titers at the lower detection limit and low-quality field sera obtained from wild boar might hamper data interpretation. To ensure serological testing with precise and resilient results, 4 commercially available ELISA kits were experimentally compared. This study provides comprehensible insight into the performance of indirect and competitive ELISA kits. Competitive ELISA kits included in the study detect antibodies against ASFV proteins p32 (ID.vet ASF Competition test) and p72 (Ingenasa Ingezim PPA COMPAC). Indirect screening assays cover detection of antibodies against proteins p32, p62, and p72 (ID.vet ASF indirect screening test), as well as cd312 and p30 (Ingenasa Ingezim ASFV-R). We assessed performance of these kits by employing sera derived from experimental ASFV infection, as well as various wild boar field sera. In conclusion, we determined the screening pipeline with the highest precision, enabling monitoring of seropositive suids and disease progression dynamics upon infection with different ASFV variants in the future.
214